Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

33.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric... 
Via FinancialNewsMedia
Topics Economy
News headline image
The Ruble Is Rubble ↗
MSCI says Russian companies are 
Via Talk Markets
News headline image
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer ↗
Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant... 
Via Benzinga
News headline image
Recap: Alkermes Q4 Earnings ↗
  Alkermes (NASDAQ:ALKS) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For February 16, 2022 ↗
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. 
Via Benzinga
News headline image
Alkermes Has Launched Employee Resource Groups
SOURCE: Alkermes 
Via 3BL Media
News headline image
One Overdose Is Too Many
SOURCE: Alkermes 
Via 3BL Media
News headline image
Alkermes's Return On Capital Employed Overview ↗
According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31%... 
Via Benzinga
News headline image
56 Biggest Movers From Yesterday ↗
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead... 
Via Benzinga
News headline image
Why Are Alkermes Shares Trading Higher Today? ↗
Alkermes plc's (NASDAQ: ALKS) Q4 sales increased 16% Y/Y to $324.5 million, beating the consensus of $308.69 million. Net sales of proprietary products were $178.9... 
Via Benzinga
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
News headline image
Earnings Preview For Alkermes ↗
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
News headline image
Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia ↗
Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan)  
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2022 ↗
Upgrades 
Via Benzinga
News headline image
BioCorRx Aims To Help Combat Opioid Crisis With Implantable Naltrexone Drug Candidate BICX104 ↗
Image provided by BioCorRx of a naltrexone pellet This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
News headline image
Early Monday Report - More Moves Out Of China ↗
Before it even turned Monday in the West, China insurers are feeling the heat. 
Via Talk Markets
News headline image
Happy New Year - Sunday Edition ↗
Starting a new year - we look at tech, pharma and mining stocks and their goings-on. 
Via Talk Markets
News headline image
Our Collective Responsibility to Respond Effectively to the Climate Crisis
SOURCE: Alkermes 
Via 3BL Media
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021 ↗
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
News headline image
Alkermes in Action: Giving Tuesday
SOURCE: Alkermes 
Via 3BL Media
News headline image
Alkermes Celebrates National Family Caregivers Month
SOURCE: Alkermes 
Via 3BL Media
News headline image
75 Biggest Movers From Yesterday ↗
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers... 
Via Benzinga
News headline image
Janssen Partially Terminates Nanoparticle License Agreement With Alkermes ↗
Alkermes plc (NASDAQ: ALKS) stock is trading lower after announcing that Janssen, a unit of Johnson & Johnson (NYSE: JNJ), has provided notice of its... 
Via Benzinga
News headline image
Why Alkermes Stock Is Sinking Today ↗
Johnson & Johnson partly ended two licensing agreements with the company. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
News headline image
7 A-Rated Healthcare Stocks to Buy for the Long Haul ↗
It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.